Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis

Abstract

The aim is to study the efficacy and safety of etoricoxib in the treatment of acute gout, as compared with non-steroidal anti-inflammatory drugs (NSAIDs). We conducted a computerized search of electronic databases: PubMed, EMBASE, Web of Science, China Biology Medicine disc, and Cochrane Library. The search terms were as follows: gout arthritis, tophus, etoricoxib, indometacin naproxen, diclofenac, and NSAIDs. Articles were searched from 1983 until August 2014. A manual search of peer-reviewed English documents was performed by cross-checking the bibliographies of selected studies. These trials reported pain relief as the primary outcome. Tenderness, swelling, patients' global assessments of response to treatment, and investigators' global assessments of response to treatment were reported as the secondary outcomes. All adverse events were recorded for safety assessment. Six trials including 851 patients were identified. Both etoricoxib and NSAIDs had an effect on inflammation and analgesia. Compared with indometacin and diclofenac, etoricoxib had a lower incidence of adverse events. Etoricoxib 120 mg administered orally once daily has the same efficacy on acute gout as indometacin and diclofenac. Etoricoxib is tolerated better by patients than NSAIDs such as indometacin and diclofenac.

Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis

“…Several systematic reviews and meta-analyses of etoricoxib have been carried out,[ 3 , 26 – 31 ] but few studies have focused on the efficacy of etoricoxib in the treatment of OA and RA. In 2005, a systemic review and meta-analysis on the thromboembolic cardiovascular events associated with etoricoxib by Aldington and colleagues suggested that etoricoxib increased the risk of cardiovascular events (odds ratio, 1.49; 95% CI, 0.42–5.31),[ 26 ] but GAEs were not evaluated.…”

Rational Use of Nonsteroidal Anti-Inflammatory Drugs. Clinical Guidelines

“…При этом заболевании НПВП используют в максимальных противовоспалительных дозах курсами, необходимыми для полного прекращения боли и исчезновения признаков воспаления [73][74][75]. По данным РКИ, с-НПВП (такие как эторикоксиб) не уступают н-НПВП при лечении обострения подагры [76,77]. Согласно международным рекомендациям, использование НПВП после купирования острого приступа подагры и начала гипоурикемической терапии возможно пролонгировать до 6 мес для предупреждения рецидива артрита [73,74,78].…”

Repairing effects of glucosamine sulfate in combination with etoricoxib on articular cartilages of patients with knee osteoarthritis

“…Thus, it is the only effective drug that can block the vicious pathological circle of KOA and promote the cartilage repair currently. As a specific inhibitor of cyclooxygenase-2 (COX-2) and a non-steroidal anti-inflammatory drug, etoricoxib has analgesic, antiinflammatory, and antipyretic effects [4], which has been widely used to relieve pain, reduce morning stiffness, and improve the joint function of OA and rheumatoid arthritis patients. In this study, glucosamine sulfate in combination with etoricoxib were used to treat KOA, and the mechanism for articular cartilage repair was explored, aiming to provide references for clinical KOA treatment.…”